Nyhedsanalysen

På trods af opjusterede forventninger til 2026

På trods af opjusterede forventninger til 2026 er Novo Nordisks aktiekurs onsdag faldet med ca. tre pct.

Silicon Valley00:00Mexico City00:00New York00:00Sao Paulo00:00Nuuk00:00Bangui00:00Linköping00:00Kyjiv00:00Kabul00:00Mumbai00:00Hong Kong00:00Shanghai00:00Sydney00:00Fransk Polynesien00:00Silicon Valley00:00Mexico City00:00New York00:00Sao Paulo00:00Nuuk00:00Bangui00:00Linköping00:00Kyjiv00:00Kabul00:00Mumbai00:00Hong Kong00:00Shanghai00:00Sydney00:00Fransk Polynesien00:00Silicon Valley00:00Mexico City00:00New York00:00Sao Paulo00:00Nuuk00:00Bangui00:00Linköping00:00Kyjiv00:00Kabul00:00Mumbai00:00Hong Kong00:00Shanghai00:00Sydney00:00Fransk Polynesien00:00Silicon Valley00:00Mexico City00:00New York00:00Sao Paulo00:00Nuuk00:00Bangui00:00Linköping00:00Kyjiv00:00Kabul00:00Mumbai00:00Hong Kong00:00Shanghai00:00Sydney00:00Fransk Polynesien00:00

1

2

3

4

5

6

7

8

9

10

11

12